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Abstract
Background—Oral immunotherapy (OIT) is a promising treatment for food allergy. Studies are
needed to elucidate mechanisms of clinical protection, and to identify safer and potentially more
efficacious methods for desensitizing patients to food allergens.
Objective—We established a mouse model of OIT in order to determine how dose or form of
antigen may affect desensitization, and to identify mechanisms of desensitization.
Methods—Increasing doses of egg white or ovomucoid as OIT were administered orally to
sensitized mice. Impact of OIT on anaphylaxis elicited by oral allergen challenge was determined.
Allergen-specific antibody and cytokine responses, and mast cell and basophil activation in
response to OIT was measured. Gene expression in the small intestine was studied by microarray
and real-time PCR.
Results—OIT resulted in desensitization but not tolerance of mice to the allergen. OIT did not
result in desensitization of systemic effector cells, and protection was localized to the
gastrointestinal tract. OIT was associated with significant changes in gene expression in the
jejunum, including genes expressed by intestinal epithelial cells. Extensively heated ovomucoid
that does not trigger anaphylaxis when given orally to sensitized mice was as efficacious as native
ovomucoid in desensitizing mice.
Conclusions—OIT results in clinical protection against food-induced anaphylaxis through a
novel mechanism that is localized to the intestinal mucosa and is associated with significant
changes in small intestinal gene expression. Extensively heating egg allergen decreases
allergenicity and increases safety while still retaining the ability to induce effective
desensitization.
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INTRODUCTION
Food allergies affect 3% of the overall population and up to 4–6% of children.1 From 1997
to 2007, the prevalence of reported food allergy increased 18% among children under 18
years of age.2 Currently, there is no cure for food allergy and management remains
avoidance of the offending food.3 Interventions that would lessen the risk of anaphylaxis
would have a major impact on the quality of life, morbidity, and mortality.
Subcutaneous immunotherapy has been used as treatment for other allergic diseases, such as
allergic rhinitis, venom allergy and allergic asthma, but has not been successful in food
allergy due to high rates of systemic reactions.4, 5 There is an increasing interest in oral
immunotherapy (OIT) for the treatment of food allergy, and several clinical trials have
shown promising results.6–10 Most subjects tolerate significantly more allergen by the end of
the study compared to their baseline. Adherence suffers from the high prevalence of side
effects and clinical reactivity returns after discontinuation of OIT in a majority of treated
subjects, demonstrating desensitization but not tolerance.911
Extensive heating can render milk and egg allergens tolerable to the majority of milk- and
egg-allergic patients. When tolerated, introducing extensively heated antigens into the diet
of allergic individuals may accelerate resolution of clinical reactivity to foods. Inclusion of
extensively heated egg or milk into the diet appears to be well-tolerated and the majority of
subjects go on to develop tolerance to unheated egg or milk. 12–14
Immunologic changes have been associated with desensitization in OIT clinical trials,
including decreased basophil reactivity, decreased skin prick test wheal size , increased
serum antigen-specific IgG4, and salivary IgA, and increased peripheral
CD4+CD25+FOXP3+ regulatory T cells.6, 8–10, 15 Similar immune changes have been
observed after inclusion of extensively heated milk into the diet, supporting the hypothesis
that this may be functioning as an immunotherapy facilitating development of immune
tolerance.16, 17 However, it is not known to what extent these immunologic changes
contribute to clinical protection, and this is difficult to test in human subjects.
OIT is a promising treatment and potential cure for food allergy, but issues of safety and
long-term efficacy remain.18 Mechanisms of clinical protection are difficult to investigate in
human subjects, and the gastrointestinal mucosa cannot be practically accessed for study. To
address these needs, we established a murine model of OIT and herein use this model to
study mechanisms of clinical protection by OIT and the use of heat-modified allergens.
METHODS
Mice
Female C3H/HeJ mice were purchased from NCI (Frederick, MD). Mice were maintained in
filter-top cages under specific pathogen-free conditions. The Institutional Animal Care and
Use Committee at Mount Sinai School of Medicine approved all procedures.
Sensitization of mice
Mice were sensitized by intragastric administration of 1 mg ovalbumin (OVA, grade V,
Sigma Chemicals, St. Louis, MO) or ovomucoid (OM, Sigma) plus 10 μg cholera toxin (List
Biologicals, Campbell, CA, USA)as adjuvant weekly for six weeks.
Administration of oral immunotherapy (OIT)
Pilot experiments were done comparing the administration of antigen as OIT by daily
gavage or through the drinking water, with the two methods being equally effective. Egg
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white was obtained from organic eggs and protein content measured by Bradford assay. Egg
white was used as OIT primarily due to cost, but for sensitization and challenge purified
allergens provide more consistent responses. An increasing dose of egg protein was
administered daily for 14 days: 1 mg (days 1,2), 5 mg (days 3,4), 10 mg (days 5–7), 25 mg
(days 8,9), 50 mg (days 10–14). The dose was calculated based on a drinking volume of 5
ml/day. For experiments using extensively heated and native OM as OIT, mice received OM
by daily gavage at half the dose of that used for whole egg white protein, (increasing doses
from 0.5 mg to 25 mg). This dose of OM was equivalent to the dose of OVA provided in
whole egg white. OM was heated as a solution in a boiling water bath for 30 min.19
Allergen challenge
Mice were orally challenged with 50 mg OVA or 25 mg OM one day or two weeks after
discontinuation of OIT. Mice were intraperitoneally injected with 1–100 μg of OVA in 0.1
ml PBS. Anaphylaxis severity was graded by symptom score 20 and body temperature
measured (by rectal thermometer, World Precision Instruments, Sarasota, FL) 30 minutes
after challenge. The symptom score was: 0 = no symptoms; 1 = scratching around the nose
and head; 2 = puffiness around eyes and mouth; 3 = wheezing, labored respiration; 4 = no
activity after prodding.
Assessment of antigen-specific immunoglobulins
Blood samples were obtained before allergen challenge. OVA- and OM-specific IgE was
measured by capture ELISA using DIG-labeled OVA or OM as detection.21 OVA-specific
IgA, IgG1, and IgG2a were measured by ELISA using biotinylated monoclonal detection
antibodies (all from BD Biosciences, San Diego, CA). Secreted intestinal antibodies were
measured in lavage obtained by flushing the entire excised small intestine with 4 ml of PBS
containing complete protease inhibitor (Roche, Indianapolis, IN).
Antigen-specific cytokine production
Spleens or mesenteric lymph nodes were removed after challenge and cells isolated and
plated with OVA or OM (100 μg/ml) for 72 h. Cytokine production was measured by
ELISA (eBioscience, San Diego, CA).
Mast cell and basophil activation assays
Blood was collected in heparinized tubes, diluted 1:1 with RPMI, and incubated at 37 ºC for
60 min with 10 – 100 μg/ml of OVA or media alone. As additional controls, cells were
incubated in U-bottom 96-well plates that had been coated overnight with 2 μg of anti-IgE
(R35–72, BD Biosciences) or rat IgG1 (eBioscience) as isotype control. Red blood cells
were lysed, and cells were fixed and stained for CD49b and IgE to detect basophils, and
CD200R as an activation marker. 22 CD3 and CD19 were used to gate out B and T cells.
Peritoneal lavage was collected and cells were stimulated as above. Cells were stained for c-
kit and IgE to detect mast cells, and CD107a (LAMP-1) as an activation marker.23 All
antibodies were from eBioscience (San Diego, CA).
Assessment of intestinal permeability
One day after discontinuing OIT, mice were euthanized, and 10 cm of jejunum were excised
starting from the ligament of Treitz. Tissue was mounted in Ussing Chambers (Physiologic
Instruments, San Diego, CA). Resistance and mucosal-to-serosal flux of FITC-dextran (3–4
kD, Sigma) measurements were obtained as described previously.24
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Intestinal gene expression
Intestine was harvested 24 h after discontinuation of OIT. Two pieces of jejunum obtained 0
and 10 cm from the Ligament of Treitz were obtained. Total RNA was isolated with Trizol
(Invitrogen) followed by RNA clean-up with RNeasy mini-kit (Qiagen, Valencia, CA).
Microarray analysis was performed by Miltenyi (Cologne, Germany) using Agilent whole
mouse genome oligo microarrays (8 × 60K). Paired analysis on 5 control and 5 OIT-treated
tissues was performed using Cy3-labeled and Cy5-labeled cRNA. Gene expression was
verified by real-time PCR using SYBR green master mix and primers (all from Invitrogen).
Epithelial cells from 10–15 cm of mid-small intestine (predominantly jejunum) were
isolated by EDTA treatment and RNA was isolated with an RNeasy mini-kit.
Statistical analysis
Student’s t-test or Mann-Whitney Rank Sum test was used for determining statistical
significance (p < 0.05) between continuous variables, and a paired t-test or Wilcoxon Signed
Rank test was used when comparing different time points.
RESULTS
OIT reduces anaphylaxis by desensitization in a murine model of food allergy
To determine the effect of OIT in a murine model of food–induced anaphylaxis, C3H/HeJ
mice were orally sensitized to OVA or OM and administered OIT as described in Methods.
Mice were then orally challenged with OVA or OM. OIT-treated mice were significantly
protected from OVA- or OM-induced anaphylaxis as compared to controls (p<0.001 for
OVA, p<0.01 for OM; based on body temperature and symptom scores). (Figure 1) After
discontinuing OIT for two weeks, mice were re-challenged to assess tolerance. OIT-treated
mice were no longer protected from anaphylaxis, indicating that OIT induced clinical
protection through desensitization, not immune tolerance.
OIT induces an increase in OVA-specific serum IgE and IgA
OVA-specific serum immunoglobulins were measured after OIT treatment prior to
challenge. A significant increase in OVA-specific IgE and IgA was observed in OIT-treated
mice as compared to controls. (Figure 2a) Serum OVA-specific IgG1 and IgG2a, which
have been shown to inhibit IgE-triggered mast cell activation 25, were not significantly
different between OIT-treated mice and controls. Measurements of OM-specific serum IgE,
IgA, IgG1, and IgG2a in OM OIT-treated mice were similar (data not shown). OVA-specific
IgA in gut lavage could be readily detected in OVA-sensitized mice, but was not
significantly increased by the administration of OIT (data not shown). It is possible that the
high concentration of antigen in the gut during OIT interferes with our ability to detect
OVA-specific IgA within the gut lumen, and therefore we do not rule out a role for mucosal
IgA in protection against oral OVA- or OM-induced anaphylaxis.
OIT is associated with a broad suppression of cytokines
The impact of OIT on antigen-specific T cell responses was assessed by re-stimulating
splenocytes with OVA in vitro and measuring cytokine secretion. Antigen-specific IL-13,
IL-10, and IFN-γ responses were all significantly reduced in OIT-treated mice as compared
to controls, indicating broad suppression rather than skewing of T cell responses. IL-4 was
near or below the level of detection. Suppression of IL-13 and IFN-γ was also observed in
the mesenteric lymph node of mice receiving OIT (data not shown). When OIT was
discontinued for two weeks, a sustained suppression of cytokines was observed in OIT-
treated mice as compared to controls despite the return of clinical responsiveness. (Figure
2b)
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OIT results in decreased intestinal barrier function
Gastrointestinal side effects have been identified as a major early obstacle to OIT
compliance.26 In order to determine the impact of OIT on intestinal physiology, segments of
jejunum were collected from OIT-treated mice as well as controls and mounted in Ussing
chambers. Epithelial barrier function was measured by electrical resistance as well as
luminal-to-serosal flux of FITC-dextran. (Figure 3) OIT resulted in a significant decrease in
resistance, and a significant increase in luminal to serosal flux of FITC-dextran, indicating a
decrease in epithelial barrier function.
High-dose OIT is required for clinical protection
Low doses of antigen preferentially elicit regulatory T cells that can prevent systemic
immune responses in classic oral tolerance studies.27 To determine if low-dose OIT could be
effective, OVA-sensitized mice were administered either a daily low dose of 1 mg (the dose
typically used in low-dose tolerance studies28) or escalating daily doses of up to 50 mg (high
dose, or the standard OIT used in this model) for two weeks and then orally challenged with
50 mg of OVA. Upon oral challenge, high-dose OIT-treated mice were protected against
anaphylaxis (p<0.001), while low-dose OIT-treated mice were not. (Figure 4)
Extensively heated antigen effectively desensitizes mice
We have previously shown that heating of OVA or OM abolishes their capacity to trigger
anaphylaxis when given orally, but not systemically, to sensitized mice.19 We investigated
whether this non-reactogenic form of antigen could be effective when administered as OIT.
Mice administered either heated or native OM as OIT were completely protected against
anaphylaxis as compared to controls. (Figure 5) These data together with our previous work
on heated egg allergens demonstrate that allergens can be modified to reduce risks of
systemic anaphylaxis, yet still maintain their full desensitizing capacity.
OIT shifts the threshold of allergen reactivity without desensitizing systemic effector cells
To test if OIT leads to desensitization of systemic effector cells, we performed activation
assays with peripheral blood basophils and peritoneal mast cells. Blood from OIT-treated or
control mice was incubated with OVA in vitro, followed by assessment of basophil
activation by flow cytometry. Basophils were detected as CD49b+ IgE+ cells, and activation
measured by up-regulation of CD200R. Activation of blood cells with plate-bound anti-IgE
induces upregulation of CD200R on basophils, while plate-bound isotype control does not
(Supplemental Figure). Basophils from untreated OVA-sensitized mice upregulated
CD200R in response to OVA stimulation, and this was not suppressed in OIT-treated OVA-
sensitized mice. (Figure 6a) Activation of peritoneal mast cells (c-kit+ FcεRI+) in response
to OVA stimulation in vitro was measured by upregulation of the marker LAMP-1
(CD107a). Activation of peritoneal cells with plate-bound anti-IgE induces upregulation of
LAMP-1 on mast cells, while isotype control does not (Supplemental Figure). LAMP-1 was
upregulated in response to OVA stimulation in untreated sensitized mice, and to a similar
extent in OIT-treated sensitized mice. (Figure 6b, and Supplemental Figure)
Because of this lack of evidence for systemic effector cell desensitization, we hypothesized
that clinical protection against food-induced anaphylaxis may be occurring locally within the
intestinal mucosa. To test this, OVA-sensitized mice were challenged by either the oral route
or systemically by low-dose intraperitoneal injection (using 0.2 % of the dose given orally).
OIT-treated mice were protected against anaphylaxis induced by oral challenge, but were
not substantially protected against anaphylaxis induced by systemic challenge. (Figure 6c)
To determine if OIT changes the threshold of reactivity to systemically administered
allergen, we performed a graded allergen challenge given by the intraperitoneal route (1, 10,
Leonard et al. Page 5
J Allergy Clin Immunol. Author manuscript; available in PMC 2013 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
and 100 μg OVA given 30 min apart) (Figure 6D). Control mice responded to 10 μg of
OVA with a significant drop in body temperature. At this dose, OIT-treated mice had
cutaneous symptoms (symptom score of 2), but no significant drop in body temperature. At
100 μg of OVA, OIT-treated and control mice had significant drops in body temperature,
but there was a statistically significant difference in the magnitude of the body temperature
drop. These data indicate that there was a shift in the threshold of antigen required to induce
symptoms in OIT-treated mice, although the level of protection was not as great as that in
response to oral allergen challenge.
OIT induces significant changes in intestinal gene expression
To begin to understand the impact of OIT locally within the gastrointestinal tract, we
performed whole-genome microarray analysis on jejunum from sensitized control mice
compared to those who had undergone OIT. Genes regulated at least 2-fold in at least 4 of 5
control:OIT comparisons were identified. 23 genes were found to be significantly down-
regulated (Table 1). These could be broadly grouped into two categories: digestive enzymes
such as trypsin, carboxypeptidase, lipase, and amylase; and antimicrobial peptides such as
alpha-defensins. Down-regulation of representative genes was confirmed by real-time PCR
(Figure 7). Several of these genes, such as alpha-defensins and trypsins, are expressed
primarily by Paneth cells. To confirm small intestinal expression of these target genes,
expression of two representative genes, pancreatic lipase (pnlp) and trypsin 4 (try4) was
examined in segments from proximal to distal small intestine, carefully cleaned of
mesentery. Gene expression was maximal in the duodenum, and decreased from jejunum to
ileum. Small intestinal crypt epithelium was then isolated from 10–15 cm of mid-small
intestine (predominantly jejunum), and expression of pnlp and try4 compared between full-
thickness intestine and isolated epithelium. Expression was enriched > 60-fold for pnlp, and
> 90-fold for try4 in isolated epithelial cells as compared to full-thickness intestine from the
same region. These data show that administration of OIT leads to the regulation of a subset
of genes in the intestine, including those expressed by intestinal epithelial cells, that have
not previously been associated with food allergy.
DISCUSSION
OIT is a promising therapy for food allergy with mechanisms of clinical protection that are
not well understood. We have developed a murine model of OIT for the treatment of food-
induced anaphylaxis that induces clinical protection and is dependent on continued exposure
to allergen. This response in sensitized mice closely resembles the typical human response
to OIT. Using this model, we have generated two main novel findings. The first is that a
major component of the mechanism of clinical protection is localized to the gastrointestinal
tract and is associated with significant changes in intestinal gene expression. The second is
that extensively heated antigen that is unable to elicit anaphylaxis can effectively desensitize
mice.
Immunologic studies from human OIT trials have shown variable effects on antigen-specific
IgE and consistent increases in antigen-specific IgG4. Our data indicates that clinical
reactivity to food allergens can be abrogated without reducing allergen-specific IgE or
increasing allergen-specific IgG. IgA is one potential mechanism of protection. We observed
a significant increase in serum allergen-specific IgA associated with OIT, but could not
confirm an increase in secreted allergen-specific IgA. Strait et al recently reported that IgA
could suppress anaphylaxis by neutralizing absorbed antigen in the circulation rather than by
preventing uptake of antigen. 29 We did observe a shift in the threshold of reactivity to
allergen given systemically, suggesting that a component of clinical protection may be
provided by neutralization by allergen-specific IgA. Kulis et al have recently found that
changes in salivary IgA are correlated with the amount of tolerated peanut protein after
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sublingual immunotherapy to peanut in humans 15. Further studies are needed to determine
if IgA is a marker or a mechanism of clinical protection.
Hypo-responsiveness of allergic effector cells, as measured by skin-prick test or in vitro
basophil activation, has been variably reported in human OIT trials. It is theorized that mast
cells and basophils are degranulated gradually by immunotherapy until they become
unresponsive or are in a refractory state. 30 Skin-prick tests have been observed to be
unchanged compared to placebo 8 or decreased 9, 10, and in vitro basophil activation tests
have been shown to be unchanged 31 or decreased 32. Our current results showed that
administration of OIT did not result in any changes in responsiveness of peripheral blood
basophils or peritoneal mast cells to activation. Basophil activation assays were performed
in whole blood and would therefore reflect the antibody milieu. Mast cells have been shown
to be the primary cells responsible for systemic anaphylaxis in mice after sensitization with
cholera toxin adjuvant33, 34, with basophils playing a minor role 34. Our results are
consistent with those reported by Skripak et al, where significant clinical protection was
observed despite a lack of significant effect of OIT on tissue mast cells compared to
placebo.8 We observed that clinical protection in response to OIT was maximal in response
to allergen challenge of the gastrointestinal tract. This may be in part due to neutralization
by IgA, although we could not confirm an increase in secreted allergen-specific IgA. 34
Microarray studies showed that OIT was associated with a significant downregulation of
gene expression in the proximal jejunum. Genes could be divided into two main categories:
digestive enzymes such as proteases, lipases, and amylases; and anti-microbial peptides (α-
defensin-related peptides). Expression was confirmed in the duodenum and proximal
jejunum and at least for the two representative genes tested further was found to be
expressed primarily by the epithelium. A number of digestive enzymes, including trypsin,
are expressed by intestinal Paneth cells that are an important source of anti-microbial
peptides including α-defensins. The function of these enzymes in the Paneth cell remains
unknown, although some enzymes are involved in proteolytic processing of anti-microbial
peptides.35 We did not address pancreatic expression of these enzymes, but the lack of
chronic adverse reactions to OIT suggests that there was no global malabsorption due to
downregulation of digestive enzymes. The link between these changes in gene expression
and clinical protection needs to be determined, as does the applicability of these findings to
the human response to OIT. These findings point to intriguing gastrointestinal mechanisms
that may underlie clinical responsiveness to food allergens.
Persistent side effects are a roadblock to the adoption of OIT as a widespread therapy for
food allergy. These include gastrointestinal side-effects, and consistent with this we have
observed that OIT is associated with changes in epithelial barrier function. This is likely due
to local effector cell activation that is known to modulate the epithelial barrier.36 Clinical
studies have shown that a majority of egg- and milk-allergic individuals can tolerate baked
egg or milk and it is anticipated that incorporating heated forms of allergen into their diet
will accelerate resolution of their allergy.12–14 Furthermore, assessment of intestinal
permeability in these subjects has shown no negative effects of incorporation of extensively
heated egg or milk into the diet on intestinal barrier function.12, 13 We have previously
shown that heated egg or milk allergens cannot elicit anaphylaxis by the oral route in
sensitized mice due to changes in uptake of intact antigen across the intestinal mucosa.19,37
In this study, we found that heated egg allergen can nevertheless be used as OIT, and is as
effective as native antigen in suppressing anaphylaxis in mice.
In summary, we have shown using a mouse model of OIT for experimental food allergy that
desensitization is associated with a boosting of antigen-specific serum IgA as well as
significant changes in gastrointestinal gene expression. These findings need to be verified in
human subjects as the mouse model does not replicate all features of human food allergy,
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such as dependence on an experimental adjuvant to induce sensitization and the requirement
for relatively high oral challenge doses to induce objective symptoms. Our results with
heated egg allergens can be translated into an alternative form of OIT that may be safer, lead
to fewer side effects and increase adherence to therapy in clinical trials. Modifications of
allergens other than egg or milk to alter their handling in the intestinal mucosa may also be
an effective approach to generating safer allergens for use in OIT.
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Key Messages
• The mechanism of clinical protection induced by OIT in mice is localized to the
gastrointestinal tract and is associated with significant changes in intestinal gene
expression.
• Extensively heated antigen that is unable to elicit anaphylaxis can effectively
desensitize mice when used as OIT.
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Figure 1. Oral immunotherapy (OIT) results in desensitization but not tolerance to OVA or OM
OVA- and OM-sensitized mice were administered OIT, or left untreated (Control). Mice
were orally challenged (on OIT), and again two weeks after discontinuation of OIT (off
OIT). 30 minutes after challenge, body temperature was measured (left) and a clinical score
was assigned (right).
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Figure 2. Immunologic changes associated with OIT in mice
Mice were orally sensitized to OVA, followed by administration of egg white OIT. (A)
OVA-specific IgE, IgG1, IgG2a, and IgA measured in serum obtained on the last day of
OIT. (B) Cytokine secretion from OVA-restimulated spleen cells obtained two weeks after
OIT discontinuation. * p < 0.05
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Figure 3. OIT decreases gastrointestinal epithelial barrier function
Mice were orally sensitized to OVA, followed by administration of egg white OIT on days
0–14. On day 15, segments of jejunum were removed and mounted in Ussing chambers.
Transmural resistance was measured at baseline (left), and luminal to serosal transport of
FITC-dextran was measured over a 90-minute period (right). **p<0.01.
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Figure 4. High dose OIT is required for clinical protection against OVA-induced anaphylaxis in
sensitized mice
OVA-sensitized mice were administered high-dose or low-dose fresh egg white OIT on days
0–14, or left untreated (Control). Mice were orally challenged on day 15. 30 minutes after
challenge, body temperature was measured (left) and a clinical score was assigned (right).
Leonard et al. Page 15
J Allergy Clin Immunol. Author manuscript; available in PMC 2013 June 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5. Extensively-heated OM protects mice against anaphylaxis
OM-sensitized mice were administered native or heated-OM OIT on days 0–14, or left
untreated (Control). Mice were orally challenged with native OM on day 15. 30 minutes
after challenge, body temperature was measured (left) and a clinical score was assigned
(right).
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Figure 6. Clinical protection is localized to the gastrointestinal tract
OVA-sensitized mice received egg white OIT on days 0–14. On day 15: (A) Peripheral
blood basophil activation. *p<0.05 versus naïve. (B) Peritoneal mast cell activation. n=5 /
group. **p<0.01 versus unstimulated. (C) Body temperature before and after challenge. (D)
Body temperature after graded ip dose challenge to OVA.
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Figure 7. OIT significantly alters intestinal gene expression
(A) Jejunal gene expression of pancreatic lipase (pnlp), trypsin 4 (try4), trypsin 5 (try5) and
GP2 was measured by PCR. (B) Expression of pnlp and try4 in proximal and mid-
duodenum, jejunum, and proximal and distal ileum. Expression of pnlp and try4 in isolated
intestinal epithelial cells (IEC) compared to full-thickness intestine (right).
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Table 1
List of genes regulated by OIT in 4 of 5 comparisons
Gene Fold Change SEM
Trypsin 5 −173.1 14.5
Carboxypeptidase B2 −143.9 66.2
Amylase −124.8 53.9
Trypsin 4 −114.5 15.8
Pancreatic Lipase −111.1 11.4
Amylase 2a5 −50.9 15.3
Amylase 1 −45.8 14.2
Trypsin 1 −38.8 7.8
Elastase 2A −31.1 9.5
Elastase 3B −29.9 5.4
Carboxypeptidase A2 −27.1 7.9
Chymotrypsin C −21.5 8.0
Carboxypeptidase A1 −19.8 1.2
Syncollin −18.3 8.6
Phospholipase A2 −12.7 3.4
Protein disulfide isomerase a2 −12.3 3.8
Carboxyl Ester Lipase −11.1 4.2
GP2 −10.1 2.6
Chymotrypsinogen B1 −8.2 1.1
α-defensin, RS2 −7.8 2.0
α-defensin, RS12 −5.5 1.5
α-defensin, RS4 −5.2 1.1
VH mRNA −3.0 0.6
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